Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids

British Journal of Clinical Pharmacology

Volumn 56, Issue 3, 2003, Pages 327-330

  Hesselink, Dennis A ^a,b   Ngyuen, Hien ^a   Wabbijn, Marike ^a   Smak Gregoor, Peter J H ^a   Steyerberg, Ewout W ^a   Van Riemsdijk, Iza C ^a   Weimar, Willem ^a   Van Gelder, Teun ^a,b  

^a Department of Internal Medicine ^*  (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Corticosteroids; Drug interactions; Kidney transplantation; Pharmacokinetics; Tacrolimus

Indexed keywords

CORTICOSTEROID; DACLIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; TACROLIMUS;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MONITORING; DRUG USE; DRUG WITHDRAWAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; TACROLIMUS;

EID: 0041317355     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0306-5251.2003.01882.x     Document Type: Article

References (14)

1. Winkler M, Christians U. A risk-benefit assessment of tacrolimus in transplantation. Drug Saf 1995; 12: 348-357.
2. Oellerich M, Armstrong VW, Schutz E, Shaw LM. Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus. Clin Biochem 1998; 31: 309-316.
3. Krahenbuhl S, Menafoglio A, Giostra E, Gallino A. Serious interaction between mibefradil and tacrolimus. Transplantation 1998; 66: 1113-1115.
4. Chenhsu RY, Loong CC, Chou MH, Lin MF, Yang WC. Renal allograft dysfunction associated with rifampin-tacrolimus interaction. Ann Pharmacother 2000; 34: 27-31.
5. Moreno M, Latorre A, Manzanares C, et al. Clinical management of tacrolimus drug interactions in renal transplant patients. Transplant Proc 1999; 31: 2252-2253.
6. Spencer CM, Goa KL, Gillis JC. Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 1997; 54: 925-975.
7. Zhang Y, Benet LZ. The gut as a barrier to drug absorption. combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 2001; 40: 159-168.
8. Hesse CJ, Baan CC, Balk AH, Metselaar HJ, Weimar W, van Gelder T. Evaluation of the new EMIT enzyme immunoassay for the determination of whole-blood tacrolimus concentrations in kidney, heart, and liver transplant recipients. Transplant Proc 2002; 34: 2988-2990.
9. Squifflet JP, Vanrenterghem Y, van Hooff JP, Salmela K, Rigotti P. Safe withdrawal of corticosteroids or mycophenolate mofetil: results of a large, prospective, multicenter, randomized study. Transplant Proc 2002; 34: 1584-1586.
10. Tortorice KL, Heim-Duthoy KL, Awni WM, Rao KV, Kasiske BL. The effects of calcium channel blockers on cyclosporine and its metabolites in renal transplant recipients. Ther Drug Monit 1990; 12: 321-328.
11. Schrama YC, Koomans HA. Interactions of cyclosporin A and amlodipine: blood cyclosporin A levels, hypertension and kidney function. J Hypertens 1998; 16(Suppl 4): S33-S38.
12. Dunn CJ, Wagstaff AJ, Perry CM, Plosker GL, Goa KL. Cyclosporin an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral) in organ transplantation. Drugs 2001; 61: 1957-2016.
13. Christians U, Schmidt G, Bader A, et al. Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. Br j Clin Pharmacol 1996; 41: 187-190.
14. Seifeldin RA, Marcos-Alvarez A, Gordon FD, Lewis WD, Jenkins RL. Nifedipine interaction with tacrolimus in liver transplant recipients. Am Pharmacother 1997; 31: 571-575.